TICKERNERD
Menu
PHGEPHGEIndustrials · Aerospace & Defense

PHGE Stock Forecast: BiomX, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.13
−2.83% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$1.5M
Ticker Nerd rank
33 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−7.5%
1M
−29.0%
YTD
−92.8%
1Y
−98.7%
From 52W high
−98.9%
From 52W low
0.0%
$0
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHGE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BiomX, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
66
Volatility
62
Issuance
54
Growth
42
Quality
30
Revisions
25
Value
25
Momentum
22

Size (98): Smaller than most of the companies we track.

Momentum (22): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PHGE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHGE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26PHGE

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Mar 2026HC Wainwright & Co.DowngradeNeutral—
26 Nov 2025HC Wainwright & Co.ReiteratesBuy—
25 Nov 2025HC Wainwright & Co.MaintainsBuy—
20 Aug 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025HC Wainwright & Co.MaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.MaintainsBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
8 Jan 2025HC Wainwright & Co.MaintainsBuy—
8 Jan 2025HC Wainwright& Co.MaintainsBuy—
16 Aug 2024HC Wainwright & Co.ReiteratesBuy—
28 May 2024Laidlaw & Co.InitiatesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Apr 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024HC Wainwright & Co.ReiteratesBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
9 Aug 2023HC Wainwright & Co.ReiteratesBuy—
15 May 2023HC Wainwright & Co.MaintainsBuy—
10 Nov 2022Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHGE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PHGE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

BiomX, Inc. (PHGE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
−0.4×

Cheaper than 94% of US stocks

EV / EBITDA
−0.9×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−403.8%

Higher than 4% of US stocks

Return on assets
−62.5%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PHGE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelAerospace & Defense
CompanyMarket capTKN rank
PHGEBiomX, Inc.$1.5M
33
KITTNauticus Robotics, Inc.$6.6M
21
AIRIAir Industries Group$11.9M
31
PRZOParaZero Technologies Ltd.$16.6M
17
DUKRDuke Robotics Corp.$18.9M
17
VWAVVisionWave Holdings, Inc.$31.7M
4
DFNST3 Defense, Inc.$34.3M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BiomX, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHGE news & analysis

BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site

GlobeNewsWire · 14 Aug 2026positive

BiomX subsidiary Zorronet received a purchase order worth approximately $300,000 to build a Unified Operational Environment at a defense technology test and evaluation site.

Why it matters — This order indicates that BiomX's defense subsidiary is generating contract revenue and expanding its presence in the defense technology sector.

BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems

GlobeNewsWire · 5 Aug 2026positive

BiomX, Inc. has acquired a 10% stake in Motomea, the developer of advanced electric motor technologies for drones and autonomous systems. The agreement also includes an exclusive drone distribution license and an option for BiomX to acquire a controlling interest in Motomea.

Why it matters — This stake and the accompanying license and acquisition option could expand BiomX's presence in the drone and autonomous systems market through access to Motomea's advanced motor technologies.

BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms

GlobeNewsWire · 28 July 2026positive

BiomX and Water.IO have agreed to updated terms for the Zorronet acquisition, with the revised deal providing BiomX additional flexibility to support Zorronet.

Why it matters — The updated terms give BiomX more operational flexibility and better align both companies around Zorronet's long-term success, which could impact PHGE's strategic positioning.

FAQ

Frequently asked questions about PHGE stock

Is PHGE stock a buy right now?

Of the 1 analysts covering BiomX, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BiomX, Inc. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHGE?

As at 22 Aug 2026, BiomX, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the PHGE stock forecast for 2030?

No analyst covering BiomX, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHGE are extrapolating price history, which says nothing about the business.

How has PHGE stock performed over the past year?

BiomX, Inc. returned -98.7% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BiomX, Inc. do?

BiomX Inc. is a biotechnology company focused on developing microbiome-based therapeutics using bacteriophages to target harmful bacteria.

What is the latest news on PHGE?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site". BiomX subsidiary Zorronet received a purchase order worth approximately $300,000 to build a Unified Operational Environment at a defense technology test and evaluation site.

Company

About BiomX, Inc.

BiomX Inc. is a biotechnology company focused on developing microbiome-based therapeutics using bacteriophages to target harmful bacteria. The company applies both natural and engineered phage cocktails, as well as personalized phage treatments, to address chronic conditions where specific bacterial strains play a key role. Current programs concentrate on diseases such as cystic fibrosis, where chronic pulmonary infections are common, diabetic foot osteomyelitis, and other bacterial-driven indications. BiomX uses its BOLT platform to discover and validate proprietary bacterial targets and to design customized phage compositions against them. In addition to its therapeutic pipeline, the company operates subsidiaries and units that can collaborate with partners in areas requiring advanced bio-targeting capabilities. Founded in 2015 and headquartered in Ness Ziona, Israel, BiomX Inc. occupies a specialized niche within the health technology sector, serving pharmaceutical partners, healthcare providers, and research communities seeking precision approaches to bacterial infections.

CEO Mr. Michael Oster · 20 employees · United States · https://www.biomx.com